Inhibrx, Inc. (INBX)

Market Cap	1.62B
Revenue (ttm)	1.80M
Net Income (ttm)	-241.36M
Shares Out	47.39M
EPS (ttm)	-5.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	168,327
Open	34.31
Previous Close	34.38
Day's Range	34.01 - 34.22
52-Week Range	14.31 - 39.79
Beta	2.92
Analysts	Buy
Price Target	35.00 (+2.67%)
Earnings Date	May 6, 2024

About INBX

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of pat...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 19, 2020
• Employees: 172
• Stock Exchange: NASDAQ
• Ticker Symbol: INBX

Financial Performance

In 2023, Inhibrx's revenue was $1.80 million, a decrease of -17.88% compared to the previous year's $2.19 million. Losses were -$241.36 million, 66.2% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for INBX stock is "Buy." The 12-month stock price forecast is $35.0, which is an increase of 2.67% from the latest price.

Price Target

$35.0

(2.67% upside)

Analyst Consensus: Buy